homepage-top-section

The clinical study, dubbed COLCORONA, will assess whether colchicine will serve as an effective treatment to prevent the phenomenon of major inflammatory storm present in adults suffering from

Under the binding agreement, the companies will work together to provide solutions for coronaviruses, including SARS-CoV-2, the novel coronavirus responsible for COVID-19. GSK will make an equity investment

Myelodysplastic syndromes are a group of closely related blood cancers characterised by ineffective production of healthy red blood cells, white blood cells and platelets, which may cause anaemia

Under an exclusive global licensing and research collaboration, the companies will involve in the assessment of up to four novel preclinical targets detected by Sitryx. The new targets

According to the company, the new programme is based on data showing that ST266 significantly decreased the inflammatory response of a body in a range of diseases and

The latest deal is said to leverage an existing agreement between the two companies established in 2018 for the development of mRNA vaccines for infectious diseases. Translate Bio

Under the deal, Vir can non-exclusively access Xencor’s Xtend Fc technology to expand the half-life of novel antibodies, which are being assessed as potential treatments for patients with

The company is working with the US Food & Drug Administration (FDA) to commence a randomised, double-blind and placebo-controlled phase III clinical trial in collaboration with the Biomedical

Under material transfer and collaboration agreement, the companies will co-develop and supply potential mRNA-based coronavirus vaccine for the prevention of COVID-19 infection. The vaccine will not be supplied